Our top pick for
Sierra Oncology Inc is a biotechnology business based in the US. Sierra Oncology shares (SRRA) are listed on the NASDAQ and all prices are listed in US Dollars. Sierra Oncology employs 69 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$21.30|
|52-week range||$11.66 - $23.22|
|50-day moving average||$21.02|
|200-day moving average||$19.13|
|Wall St. target price||$33.20|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-6.42|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||-3.18%|
|1 month (2021-09-17)||2.65%|
|3 months (2021-07-17)||7.14%|
|6 months (2021-04-16)||18.80%|
|1 year (2020-10-16)||74.02%|
|2 years (2019-10-16)||7,000.00%|
|3 years (2018-10-16)||1,039.04%|
|5 years (2016-10-14)||1,083.33%|
|Gross profit TTM||$-44,818,000|
|Return on assets TTM||-40.72%|
|Return on equity TTM||-72.74%|
|Market capitalisation||$276.3 million|
TTM: trailing 12 months
There are currently 25,899 Sierra Oncology shares held short by investors – that's known as Sierra Oncology's "short interest". This figure is 12% down from 29,426 last month.
There are a few different ways that this level of interest in shorting Sierra Oncology shares can be evaluated.
Sierra Oncology's "short interest ratio" (SIR) is the quantity of Sierra Oncology shares currently shorted divided by the average quantity of Sierra Oncology shares traded daily (recently around 20719.2). Sierra Oncology's SIR currently stands at 1.25. In other words for every 100,000 Sierra Oncology shares traded daily on the market, roughly 1250 shares are currently held short.
However Sierra Oncology's short interest can also be evaluated against the total number of Sierra Oncology shares, or, against the total number of tradable Sierra Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sierra Oncology's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Sierra Oncology shares in existence, roughly 0 shares are currently held short) or 0.0079% of the tradable shares (for every 100,000 tradable Sierra Oncology shares, roughly 8 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sierra Oncology.
Find out more about how you can short Sierra Oncology stock.
We're not expecting Sierra Oncology to pay a dividend over the next 12 months.
Sierra Oncology's shares were split on a 1:40 basis on 22 January 2020. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sierra Oncology shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for Sierra Oncology shares which in turn could have impacted Sierra Oncology's share price.
Over the last 12 months, Sierra Oncology's shares have ranged in value from as little as $11.655 up to $23.215. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sierra Oncology's is 0.9407. This would suggest that Sierra Oncology's shares are less volatile than average (for this exchange).
Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.